NextCure Inc - Asset Resilience Ratio
NextCure Inc (NXTC) has an Asset Resilience Ratio of 55.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NXTC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how NextCure Inc's Asset Resilience Ratio has changed over time. See what is NextCure Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down NextCure Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NextCure Inc (NXTC) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $21.79 Million | 55.0% |
| Total Liquid Assets | $21.79 Million | 55.00% |
Asset Resilience Insights
- Very High Liquidity: NextCure Inc maintains exceptional liquid asset reserves at 55.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NextCure Inc Industry Peers by Asset Resilience Ratio
Compare NextCure Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for NextCure Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for NextCure Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 50.57% | $40.89 Million | $80.86 Million | -23.79pp |
| 2023-12-31 | 74.37% | $95.22 Million | $128.04 Million | +1.99pp |
| 2022-12-31 | 72.37% | $133.28 Million | $184.16 Million | -13.13pp |
| 2021-12-31 | 85.51% | $207.25 Million | $242.39 Million | +3.76pp |
| 2020-12-31 | 81.75% | $250.68 Million | $306.64 Million | -2.63pp |
| 2019-12-31 | 84.37% | $300.51 Million | $356.17 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $147.63 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $19.47 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more